Get the Stockscreener App
19.30
3.27%
0.615
Mesoblast Ltd Adr stock is traded at $19.30, with a volume of 101.63K.
It is up +3.27% in the last 24 hours and down -1.08% over the past month.
Mesoblast Ltd is a commercial-stage biotechnology company and a world leader in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The company's product candidates include: Ryoncil (remestemcel-L) for the treatment of steroid-refractory acute graft versus host disease, as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of an adult stem cell technology platform for commercialization.
See More
Previous Close:
$18.68
Open:
$18.78
24h Volume:
101.63K
Relative Volume:
0.51
Market Cap:
$2.49B
Revenue:
$17.20M
Net Income/Loss:
$-102.16M
P/E Ratio:
-22.81
EPS:
-0.8458
Net Cash Flow:
$-57.32M
1W Performance:
+14.62%
1M Performance:
-1.08%
6M Performance:
+17.91%
1Y Performance:
+7.89%
1-Day Range:
$18.63
$19.34
1-Week Range:
$16.79
$19.34
52-Week Range:
$9.61
$21.50
Mesoblast Ltd Adr Stock (MESO) Company Profile
Compare MESO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MESO
Mesoblast Ltd Adr
|
19.26 | 2.41B | 17.20M | -102.16M | -57.32M | -0.8458 |
|
VRTX
Vertex Pharmaceuticals Inc
|
473.05 | 120.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
768.70 | 80.15B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
865.92 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
358.81 | 47.74B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
336.21 | 37.38B | 4.98B | 69.59M | 525.67M | 0.5197 |
Mesoblast Ltd Adr Stock (MESO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-25-25 | Upgrade | Jefferies | Hold → Buy |
| Jul-18-25 | Downgrade | Jefferies | Buy → Hold |
| Dec-23-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-24-24 | Upgrade | Maxim Group | Hold → Buy |
| Aug-29-24 | Upgrade | Jefferies | Hold → Buy |
| Jul-23-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-31-23 | Upgrade | Jefferies | Hold → Buy |
| Aug-07-23 | Downgrade | Maxim Group | Buy → Hold |
| Aug-04-23 | Downgrade | Piper Sandler | Overweight → Neutral |
| Aug-04-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Mar-09-23 | Initiated | William Blair | Outperform |
| Dec-06-22 | Downgrade | Jefferies | Buy → Hold |
| Sep-06-22 | Initiated | Piper Sandler | Overweight |
| Apr-07-21 | Upgrade | Maxim Group | Hold → Buy |
| Dec-22-20 | Downgrade | Maxim Group | Buy → Hold |
| Dec-04-20 | Downgrade | Chardan Capital Markets | Neutral → Sell |
| Oct-22-20 | Initiated | RBC Capital Mkts | Sector Perform |
| Aug-14-20 | Reiterated | Maxim Group | Buy |
| May-28-20 | Reiterated | H.C. Wainwright | Buy |
| Jan-31-19 | Resumed | H.C. Wainwright | Buy |
| Mar-22-18 | Downgrade | Credit Suisse | Neutral → Underperform |
| Feb-28-18 | Reiterated | Cantor Fitzgerald | Buy |
| Aug-31-17 | Initiated | Oppenheimer | Outperform |
| Jun-08-17 | Initiated | Cantor Fitzgerald | Buy |
View All
Mesoblast Ltd Adr Stock (MESO) Latest News
Real-World Commercial Experience with Ryoncil® Shows 84% Survival of Children with SR-aGvHD After Completing 28-Days of Treatment - GlobeNewswire Inc.
Mesoblast stock reaches 52-week high at 21.05 USD - Investing.com
Mesoblast stock reaches 52-week high at 21.05 USD By Investing.com - Investing.com India
Mesoblast announces board leadership changes as company evolves By Investing.com - Investing.com India
Mesoblast Shares (ASX:MSB) Stall at Resistance After Recent Rally - thebull.com.au
ETFs Investing in Mesoblast Limited Sponsored ADR Stocks - TradingView
Why Autodesk Shares Are Trading Higher By Around 6%; Here Are 20 Stocks Moving Premarket - inkl
Jefferies upgrades Mesoblast stock to Buy on strong Ryoncil sales By Investing.com - Investing.com India
Mesoblast rides early ryoncil® momentum, tightens cash discipline, and prepares for next growth phase - Proactive financial news
Why CSX Shares Are Trading Higher By Over 4%; Here Are 20 Stocks Moving Premarket - Benzinga
Quantum Computing, Mesoblast And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Mesoblast Limited $MESO Shares Acquired by Cubist Systematic Strategies LLC - Defense World
Mesoblast secures up to US$50m in fresh funding through convertible note agreements - Biotech Dispatch
Mesoblast Secures Option for US$50 Million Convertible Note Issuance - Sharecafe
Mesoblast Enters Into Option To Issue US$50 Million Convertible Notes - ADVFN Brasil
Press Release: Mesoblast Enters Into Option To Issue US$50 Million Convertible Notes - 富途牛牛
Canaccord Genuity initiates Mesoblast stock with Buy rating on cell therapy potential - Investing.com
Company’s Banking Stock: Dissecting a -4.28% Quarterly Revenue Decline Amid Growth - investchronicle.com
Mesoblast Ltd ADR Inc. (MESO) Price Performance: A Comparative Analysis with Competitors - investchronicle.com
BILL Holdings Inc Inc. (BILL) Price Performance: A Fundamental Analysis Perspective - investchronicle.com
Mesoblast stock soars after reporting first Ryoncil sales - Investing.com
Mesoblast Targets Accelerated FDA Approval For Heart Failure Drug Revascor - Sahm
Krispy Kreme Inc (DNUT) Stock: A Year of Stock Market Ups and Downs - investchronicle.com
Why Cheetah Mobile Shares Are Trading Higher By Over 11%; Here Are 20 Stocks Moving Premarket - Benzinga
All Markets & Instruments Available to Trade - Capital.com
ASX Lunch Wrap: ASX and gold reset record highs; but Origin cuts its LNG forecast - Stockhead
Why are Mesoblast shares in a trading halt? - The Motley Fool Australia
Mesoblast Limited Initiates Trading Halt Pending Financing Announcement - TipRanks
ASX healthcare 2024 winners and losers, plus what’s next for 2025 - Stockhead
Mesoblast Stock Soars to 52-Week High, Hits $19.15 - Investing.com
Mesoblast: Undervalued Due To Remestemcel-L's Substantial Growth Potential (NASDAQ:MESO) - Seeking Alpha
MESOMesoblast Ltd ADR Short Interest - Finviz
Mesoblast Limited: Back From The Dead (NASDAQ:MESO) - Seeking Alpha
symbol__ Stock Quote Price and Forecast - CNN
10 Best Australian Stocks To Buy - Yahoo Finance
Mesoblast Ltd Share Price ADR Each Representing 10 Ord Shares SPON - Hargreaves Lansdown
Philip R. Krause, M.D., Former FDA Deputy Chief For Vaccines, Joins Mesoblast Board - Barchart.com
MESO Financial Statements & ChartsMesoblast LtdAdr MacroTrends - CMLviz
MESO Pivot Points, Technical Analysis and Moving AveragesMesoblast LtdAdr Technicals - CMLviz
Maxim Group Stick to Their Buy Rating for Mesoblast Ltd - Investing.com
The Daily Biotech Pulse: Pfizer-BioNTech Vaccine Gets Temporary UK Authorization, Ovid's Trial Disappointment, Vanda Snags FDA Nod - Yahoo Finance
Novartis secures exclusive rights for potential acute respiratory distress syndrome cell therapy - Novartis
How many stocks fighting COVID-19 have maintained their momentum? - Stockhead
The Daily Biotech Pulse: AbbVie, Allergan Agree On Divestments, Obalon Stops Obesity Balloon Sale, COVID-19 Updates - Yahoo Finance
MESO Stock Price and Chart — NASDAQ:MESO - TradingView
MSB Stock Price and Chart — ASX:MSB - TradingView — Track All Markets
Mesoblast Limited (MESO) stock price, news, quote and history - Yahoo Finance UK
MESO Stock Price | Mesoblast Ltd. ADR Stock Quote (U.S.: Nasdaq) - MarketWatch
Mesoblast Ltd Adr Stock (MESO) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.26%
0.30%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):